Clinical trials: Negative Symptoms in Schizophrenia
Schizophrenia, Negative Symptoms in Schizophrenia
Dance and Movement Therapy in Patients With Schizophrenia
Introduction: Schizophrenia is a mental disorder that starts at a young age and progresses with positive (hallucination, delusion) and negative (decreased emotional participation, reluctance) symptoms.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Disabilities Mental, Dance Therapy
- Trial name
- DMTinSchizo (NCT05500651)
- Testing
- Dance and Movement Therapy (DMT)
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Amasya University
Negative Symptoms in Schizophrenia
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
The goal of this clinical trial is to evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects with Moderate to Severe Negative Symptoms…
- Trial name
- NCT06107803
- Testing
- Roluperidone 64 mg, Olanzapine 10 MG
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Minerva Neurosciences
Schizophrenia Spectrum Disorders, Negative Symptoms in Schizophrenia
ENGAGE: Virtual Reality-based Psychotherapy for Negative Symptoms in Schizophrenia
The primary goal of this pilot study is to examine the feasibility and acceptability of a new Virtual Reality-based intervention against negative symptoms in schizophrenia spectrum disorders (SSD).
- Trial name
- ENGAGE (NCT06993831)
- Testing
- Virtual Reality-based psychotherapy
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia
Minocycline add-on to Antipsychotics for the Treatment of Negative and Cognitive Symptoms in Schizophrenia
Current medications have only a limited effect on two core symptoms of schizophrenia, negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline which has a beneficial effect in various neurological…
- Trial name
- NCT02907437
- Testing
- Minocycline, Probiotics
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Beer Yaakov - Ness Ziona Mental Health Center
Negative Symptoms in Schizophrenia, Brain Stimulation Intervention
Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
Dysfunction of the dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia. Both HD-tDCS and iTBS targeting the left DLPFC have shown therapeutic benefit.
- Trial name
- NCT07680959
- Testing
- active iTBS followed by active HD-tDCS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
A study to evaluate the long-term safety and tolerability of flexible doses of Lu AF11167 in patients with schizophrenia during the 24-week treatment period
- Trial name
- NCT03929497
- Testing
- Lu AF11167
- Where
- 30 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.
- Trial name
- NCT00986531
- Testing
- AZD8529
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Brain Stimulation, Clinical Symptoms and Cognition
The purpose of this study is to test the impact of non-invasive brain stimulation, transcranial direct current stimulation (tDCS), on auditory hallucinations, negative symptoms and cognition in schizophrenia.
- Trial name
- NCT05053451
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06388551
- Testing
- LY03017
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Negative and Cognitive Symptoms in Schizophrenia
Minocycline for the Treatment of Early-Phase Schizophrenia
Current antipsychotics have only a limited effect on two core symptoms of schizophrenia, negative symptoms and cognitive deficits.
- Trial name
- NCT00733057
- Testing
- Minocycline
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia and Disorders With Psychotic Features
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms
The purpose of this study is to investigate if minocycline limits the development of negative symptoms in early psychosis and to test via what mechanism of action this change occurs.
- Trial name
- BeneMin (NCT02928965)
- Testing
- Minocycline
- Volunteers
- 207 people
- Sponsor
- University of Manchester
Negative Type; Schizophrenic, Anhedonia
Motive-specific Intervention for Negative Symptoms in Schizophrenia
The aim of this study is to test a therapeutic intervention to reduce negative symptomatic among schizophrenia patients. Since the intervention can take place within an inpatient stay, it is a short intervention.
- Conditions
- Negative Type; Schizophrenic, Anhedonia, Apathy
- Trial name
- MoNSS (NCT04793438)
- Testing
- Motive-specific intervention, Supportive conversations
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Schizophrenia
The Effect of tDCS on Schizophrenia With Negative Symptoms
The investigators conducted a randomized controlled trial to reveal the effect of tDCS on negative symptoms in patients with schizophrenia and its underlying mechanism using the neuroimaging and electrophysiology.
- Trial name
- NCT03729791
- Testing
- tDCS
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
- Trial name
- CONVOKE (NCT05838625)
- Testing
- CT-155, Digital Control
- Where
- 54 sites in United States
- Volunteers
- 464 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
Brain Image Markers Associated With Cognitive Training and Aerobic Exercise in Schizophrenia
This study evaluates the brain correlates of Cognitive Training and Aerobic Exercise in schizophrenia. A third of participants will receive Cognitive Training plus Standard Care for schizophrenia.
- Trial name
- CORTEX-SP (NCT03509597)
- Testing
- Aerobic Exercise, Cognitive Training, Treatment as usual
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Red Salud Mental Araba
Schizophrenia
Evaluation of the H1-coil Deep TMS in the Treatment of Negative Symptoms and Cognitive Deficit in Schizophrenia
The study evaluates the feasibility of using a 4 week stimulation protocol with the deep TMS H-coils for the treatment of negative symptoms and cognitive deficit in schizophrenia patients
- Trial name
- NCT00445926
- Testing
- deep TMS H-coil
- Where
- Israel
- Sponsor
- Shalvata Mental Health Center
Schizophrenia
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients
The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia. This study will compare the sulforaphane with placebo.
- Trial name
- NCT04521868
- Testing
- Sulforaphane
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Central South University
Schizophrenia; Negative Type
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Schizophrenia patients commonly present with persistent negative symptoms which remain the main reason for dysfunction after recovery from an acute episode of psychotic symptoms.
- Trial name
- NOBLE-TMS (NCT06351514)
- Testing
- Accelerated iTBS
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Institute of Mental Health, Singapore
Schizophrenia, Negative Symptoms
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
Negative symptoms and cognitive dysfunction in schizophrenia (CDS) are core features of schizophrenia. These negative symptoms and cognitive deficits have a devastating impact on the function, employment, and social interactions…
- Conditions
- Schizophrenia, Negative Symptoms, Cognitive Dysfunction
- Trial name
- NCT01488929
- Testing
- TC-5619
- Where
- 64 sites in United States, Hungary and 4 more
- Volunteers
- 603 people
- Sponsor
- Targacept Inc.